The Phase 2/3 trial initiation is a positive operational step, but the stock is under severe pressure from dilution risk and delisting threat. Monitor for shareholder vote on authorized share increase and any preliminary efficacy/safety data from the safety run-in cohort.
Price Chart
Executive Summary
Silexion Therapeutics dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer, a key operational milestone. However, the company faces severe dilution risk from a recent warrant inducement (6.4M new warrant shares on a tiny base) and a Nasdaq delisting notice for bid price non-compliance. The trial is early-stage with no data yet, and the company's capital position remains precarious.
Key Facts
- First patient dosed in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center.
- Trial includes safety run-in (~18 patients) and randomized expansion (~166 patients); no preliminary data reported.
- Recent warrant inducement (Sept 29) created 6.4M new warrant shares on a tiny base, with a shareholder vote needed to increase authorized shares.
- Nasdaq delisting notice received Sept 25 for bid price below $1.00 for 30 consecutive days.
- Company is a clinical-stage biotech with no approved products and ongoing capital needs.
Financial Impact
Warrant inducement generated ~$0.84M in gross proceeds but added 6.4M warrant shares; dilution risk is severe relative to current share count.
Risk Factors
- Nasdaq delisting if bid price remains below $1.00; hearings panel decision pending.
- Massive dilution from warrant exercises and potential need for further capital raises.
- Early-stage trial with no data; high risk of failure in pancreatic cancer.
- Cash runway limited; additional financing likely required to complete the trial.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371798 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1746 (−13.52%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1746 (+33.56%) |
Sep 30, 2026 26d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1746 (−36.97%) |
Sep 30, 2026 26d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1746 (+37.04%) |
Sep 29, 2026 27d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1746 (+45.09%) |
Sep 29, 2026 27d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1746 (+45.16%) |
Sep 28, 2026 28d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1746 (−29.71%) |
Sep 28, 2026 28d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1746 (−29.71%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1746 (+29.71%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1746 (+58.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers